Literature DB >> 8364524

Animal and human antibodies reactive with the outer surface protein A and B of Borrelia burgdorferi are borreliacidal, in vitro, in the presence of complement.

V Sambri1, S Armati, R Cevenini.   

Abstract

Polyspecific antibodies present in ascitic fluids of mice (pMIAFs) immunized with whole Borrelia burgdorferi cells exerted borreliacidal activity in vitro when tested with complement and homologous antigen but not with heterologous B. hermsii. Similarly, monospecific mouse antibodies obtained by immunizing mice with purified preparations of outer surface protein A and B of B. burgdorferi were borreliacidal. On the contrary, mouse monospecific antibodies raised against the 41-kDa flagellar protein of B. burgdorferi did not kill borreliae in the presence of complement. A complement-mediated, in vitro, borreliacidal activity was observed in human sera from patients with Lyme disease when antibodies against OspA and/or OspB were detectable in sera by the Western blotting technique. The in vitro borreliacidal activity of human sera was evident after 14 h incubation with live B. burgdorferi spirochaetes and complement, whereas antibodies present in mouse immune ascitic fluids killed borreliae after 1 h incubation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8364524     DOI: 10.1111/j.1574-695X.1993.tb00383.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  13 in total

1.  Detection of borreliacidal antibodies in Lyme borreliosis patient sera containing antimicrobial agents.

Authors:  D A Jobe; N Rawal; R F Schell; S M Callister
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

2.  Specific antibodies reactive with the 22-kilodalton major outer surface protein of Borrelia anserina Ni-NL protect chicks from infection.

Authors:  V Sambri; A Marangoni; A Olmo; E Storni; M Montagnani; M Fabbi; R Cevenini
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Production of borreliacidal antibody to outer surface protein A in vitro and modulation by interleukin-4.

Authors:  E L Munson; B K Du Chateau; D A Jobe; S D Lovrich; S M Callister; R F Schell
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

4.  Sensitivity and specificity of the borreliacidal-antibody test during early Lyme disease: a "gold standard"?

Authors:  S M Callister; D A Jobe; R F Schell; C S Pavia; S D Lovrich
Journal:  Clin Diagn Lab Immunol       Date:  1996-07

5.  Detection of anti-Borrelia burgdorferi antibody responses with the borreliacidal antibody test, indirect fluorescent-antibody assay performed by flow cytometry, and western immunoblotting.

Authors:  J R Creson; L C Lim; N J Glowacki; S M Callister; R F Schell
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

6.  Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment.

Authors:  R K Straubinger; B A Summers; Y F Chang; M J Appel
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

7.  Interleukin-6 promotes anti-OspA borreliacidal antibody production in vitro.

Authors:  Erik L Munson; Dean T Nardelli; K H Kevin Luk; Monica C Remington; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2006-01

8.  Gamma interferon inhibits production of Anti-OspA borreliacidal antibody in vitro.

Authors:  Erik L Munson; Brian K Du Chateau; Jani R Jensen; Steven M Callister; David J DeCoster; Ronald F Schell
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

9.  Sera from OspA-vaccinated dogs, but not those from tick-infected dogs, inhibit in vitro growth of Borrelia burgdorferi.

Authors:  R K Straubinger; Y F Chang; R H Jacobson; M J Appel
Journal:  J Clin Microbiol       Date:  1995-10       Impact factor: 5.948

10.  Ability of the borreliacidal antibody test to confirm lyme disease in clinical practice.

Authors:  Steven M Callister; Dean A Jobe; William A Agger; Ronald F Schell; Todd J Kowalski; Steven D Lovrich; Jennifer A Marks
Journal:  Clin Diagn Lab Immunol       Date:  2002-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.